Sam Brusco, Associate Editor02.12.24
Smith+Nephew is premiering its newly acquired CartiHeal Agili-C cartilage repair implant, along with the Regeneten bioinductive implant at this year’s American Academy of Orthopaedic Surgeons (AAOS) meeting in San Francisco.
According to the company, both technologies are transforming how clinicians treat soft tissue repair, as well as helping to improve outcomes compared to the standard of care.
During development, the implant held breakthrough device status from the U.S. Food and Drug Administration (FDA). Agili-C earned FDA approval in 2022.
Trial results published in December 2023 showed one-year re-tear rates for medium and large full-thickness tears of the rotator cuff were reduced by 68% when the Regeneten implant was used. Smith+Nephew also said it’s assisting Achilles injury healing potential when used to augment insertional of midsubstance Achilles repair.
“As a leader in Sports Medicine, we are committed to bringing emerging technologies that address unmet clinical needs to our customers and their patients,” said Scott Schaffner, President Sports Medicine, Smith+Nephew. “Both REGENETEN and CARTIHEAL AGILI-C implants have the opportunity to set new benchmarks for standard of care across multiple joint repair indications and deliver better patient outcomes.”
If you’re attending AAOS 2024, you can find Smith+Nephew at booth 5469!
According to the company, both technologies are transforming how clinicians treat soft tissue repair, as well as helping to improve outcomes compared to the standard of care.
CartiHeal Agili-C Cartilage Repair Implant
The one-step treatment for osteochondral lesions was acquired last month. It doesn’t need donor tissue and can be used for traumatic, osteoarthritic, and about 700,000 people annually receiving cartilage repair in the U.S.During development, the implant held breakthrough device status from the U.S. Food and Drug Administration (FDA). Agili-C earned FDA approval in 2022.
Regeneten Bioinductive Implant
The collagen-based implant supports the body’s healing response to help form new tendon-like tissue to biologically augment existing tendons.Trial results published in December 2023 showed one-year re-tear rates for medium and large full-thickness tears of the rotator cuff were reduced by 68% when the Regeneten implant was used. Smith+Nephew also said it’s assisting Achilles injury healing potential when used to augment insertional of midsubstance Achilles repair.
“As a leader in Sports Medicine, we are committed to bringing emerging technologies that address unmet clinical needs to our customers and their patients,” said Scott Schaffner, President Sports Medicine, Smith+Nephew. “Both REGENETEN and CARTIHEAL AGILI-C implants have the opportunity to set new benchmarks for standard of care across multiple joint repair indications and deliver better patient outcomes.”
If you’re attending AAOS 2024, you can find Smith+Nephew at booth 5469!